We recently published an article titled Top 10 Health Information Services Stocks Outpacing The Market In 2025. In this article, we are going to take a look at where Certara, Inc. (NASDAQ:CERT) stands against the other health information services stocks.
Health Information Services stocks have become a key focus for investors as AI starts to enter more domains in 2025. Some of the most amazing gains have come in health information services stocks that are utilizing AI to improve research and services in the healthcare sector.
The healthcare information services sector allows investors to gain exposure to a number of growing and emerging technologies including cloud-backed software solutions to physician enablement platforms. Some of the companies in our list are surging based on earnings anticipation while others are increasing in share price because of their upcoming products or revenue growth.
To come up with our list of top 10 health information services stocks outpacing the broader market in 2025, we only considered stocks with a market cap of at least $2 billion that were outperforming the S&P 500 index.
25 States with the Lowest Life Expectancy in the US
Certara, Inc. (NASDAQ:CERT)
Certara, Inc. (NASDAQ:CERT) is a technology-enabled services and software products provider for market access, biosimulation in drug discovery, regulatory submissions, and preclinical and clinical research. It offers its services to biopharmaceutical companies, academic institutions, animal health, the public sector, life sciences companies, and other industries. The stock is up 43% this year and that’s not surprising considering it is a medical AI stock.
Certara, Inc. (NASDAQ:CERT) brings AI to drug development and research through its platform Certara.ai. Even though the company announces its detailed earnings on the 26th of February, preliminary numbers suggest a revenue growth of over 10%. The company’s software segment continues to drive a major chunk of the growth at 24% YoY while the services segment contributes a healthy 7%.
Bookings growth of 22% shows the company’s product is gaining traction. Analysts have started noticing the stock with Leerink Partners boosting the stock’s price target from $12 to $13 on the back of improved revenue prospects after the Chemaxon acquisition. Both revenue and profits should improve as we progress further in 2025.
Overall CERT ranks 4th on our list of the health information services stocks outpacing the market in 2025. While we acknowledge the potential of CERT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as CERT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. This article was originally published at Insider Monkey.
